Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Paulzen
Michael
M
Clement
Hans-Willi
HW
Gründer
Gerhard
G
D018759:Adrenergic Uptake Inhibitors / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000328:Adult; D000069445:Atomoxetine Hydrochloride; D001288:Attention / Q000187:drug effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use*; D011437:Propylamines / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*
D018759:Adrenergic Uptake Inhibitors; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D011437:Propylamines; D017374:Paroxetine; D000069445:Atomoxetine Hydrochloride; D019389:Cytochrome P-450 CYP2D6